Joint fluid therapy has new directions for use
The FDA has approved new labeling for Supartz, an injectable form of hyaluronic acid that is used for the treatment of pain from osteoarthritis of the knee. New directions for use now allow physicians to choose as few as three intra-articular injections for a course of therapy, instead of the previously approved five weekly injections.
Joint fluid therapy has new directions for use
The FDA has approved new labeling for Supartz, an injectable form of hyaluronic acid that is used for the treatment of pain from osteoarthritis of the knee. New directions for use now allow physicians to choose as few as three intra-articular injections for a course of therapy, instead of the previously approved five weekly injections. Supartz was originally approved by the FDA in 2001 and, according to manufacturer Smith & Nephew, is intended for patients who have failed to adequately respond to conservative, nonpharmacologic therapy and simple analgesics, such as acetaminophen.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
How Mark Cuban Cost Plus Drug Company Is Approaching Drug Pricing Transparency
October 14th 2024Erin Albert, vice president of pharmacy relations and chief privacy officer at Mark Cuban Cost Plus Drug Company, PBC, discussed drug pricing and what her company is doing to revolutionize transparency.
